Pembrolizumab After ASCT for Hodgkin Lymphoma DLBCL and T-NHL
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Hodgkin Lymphoma
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required